Our Clinical Trials
Refer a Patient
For new patient referrals, please contact:
Jessica Hochberg, MD
Jessica_Hochberg@cwpw.org
(914) 493-7997
Acute Lymphoblastic Leukemia
- AALL1331 – Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
- ACCL1333/CV185155 – A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated (PEG) L-Asparaginase
- NYMC 550 – A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
- NYMC 542 – A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma
- NYMC 558 – Phase III Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
- NYMC 567 – A multicenter Phase II Trial of Inhibition of CD26 Peptidase using Sitagliptin to Enhance Engraftment after Umbilical Cord Blood Transplantation for Adults with Hematological Malignancies – Adult patients only
- NYMC 525 – CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
- AALL1131 – A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum
- AALL1231 – A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
- AALL08B1 – Classification of Newly Diagnosed Acute Lymphoblastic Leukemia
- AALL0932 – Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-lineage Lymphoblastic Lymphoma (B-LLy)
- ACCL1033 – A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
- ACCL0934 – A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
- AALL05B1 – A Children’s Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Acute Myeloid Leukemia
- NYMC 515 – Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
- NYMC 504 – SCT Plus Immune Therapy in Average Risk AML/MDS
- NYMC 550 – A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
- NYMC 567 – A multicenter Phase II Trial of Inhibition of CD26 Peptidase using Sitagliptin to Enhance Engraftment after Umbilical Cord Blood Transplantation for Adults with Hematological Malignancies – Adult patients only
- NYMC 525 – CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
- AAML1031 – A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.
- ACCL0934 – A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
- NYMC 515 – A Pilot Study of Gemtuzumab Ozogamicin in Combination with Busulfan and Cyclophosphamide (Bu/Cy) (Immunochemotherapy) and Allogeneic Stem Cell Transplantation (AlloSCT) in Patients with High Risk CD33+ Acute Myelogenous Leukemia/Myelodysplastic Syndrome (AML/MDS)
- NYMC 504 – Allogeneic Stem Cell Transplantation Followed by Targeted Immune Therapy in Average Risk Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia (AML/MDS/JMML)
Acute Promyelocytic Leukemia
Adrenoleukodystrophy (ALD)
Aplastic Anemia
- NYMC 550 – A Single-Arm Study to Assess the Safety of Transplantation With Human Placental-Derived Stem-Cells Combined With Unrelated and Related Cord Blood in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders
- NYMC 525 – CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
- 10-CBA – A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Brain Tumors
- ACNS02B3- A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens
- ACNS1123 – Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)
- ACNS0334 – A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy without Methotrexate
- ACNS1221 – A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age
- ACNS1022 – A Phase II Randomized Trial of Lenalidomide (NSC #703813, IND#70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gilomas
- ABTRO1B1 – A Children’s Oncology Group Protocol for Collecting & Banking Pediatric Research Specimens Including Rare Pediatric Tumors
- ACNS0831 – Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years
- NYMC 165 – A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2-O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Pediatric Patients With a Recurrent Solid Tumor Receiving “ICE” Chemotherapy (IND 122872)
- ACNS0821 – Temozolomide with Irinotecan Versus Temozolomide, Irinotecan plus Bevacizumab (NSC#704865, BB-IND#7921) for recurrent/refractory Medulloblastoma/CNS PNET of Childhood, A Cog Randomized Phase II Screening Trial
Chronic Myeloid Leukemia
- NYMC 567 – A multicenter Phase II Trial of Inhibition of CD26 Peptidase using Sitagliptin to Enhance Engraftment after Umbilical Cord Blood Transplantation for Adults with Hematological Malignancies – Adult patients only
- NYMC 525 – CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
- ACNS0334 – A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy without Methotrexate
Ewing Sarcoma
- AEWS1031 – A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma.
- AEWS1221 – Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
- AEWS07B1 – Ewing Sarcoma Biology Studies
- AEWS1031 – A phase III randomized trial of adding vincristine – topotecan- cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma
Fanconi Anemia
Hemophagocytic Lymphohistiocytosis (HLH)
Hepatoblastoma
- AHEP0731 – Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment
Hodgkin Lymphoma
- AHOD1221 – A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND#117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with relapsed or Refractory Hodgkin Lymphoma
- NYMC 568 – A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab with Bombination Bhemotherapy in the Treatment of Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma Hodgkin Lymphoma Patients
- NYMC 564 – Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
- NYMC 553 – Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma
- NYMC 561 – 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
- NYMC 558 – Phase III Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
- NYMC 525 – CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Juvenile Myelomonocytic Leukemia
- ASCT1221 – A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children with Juvenile Myelomonocytic Leukemia (JMML)
- NYMC 504 – Allogeneic Stem Cell Transplantation Followed by Targeted Immune Therapy in Average Risk Myelogenous Leukemia/Myelodysplastic Syndrome/Juvenile Myelomonocytic Leukemia (AML/MDS/JMML)
Kidney Tumors
- NYMC 165 – A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2-O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Pediatric Patients With a Recurrent Solid Tumor Receiving “ICE” Chemotherapy (IND 122872)
- AREN03B2 – Renal Tumors Biology Studies
Metachromatic Leukodystropy (MCLD)
Neuroblastoma
- ANBL0032 – Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue.
- ANBL1221 – A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND#4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
- ANBL1232 – Utilizing Response & Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma
- ANBL00B1 – Neuroblastoma biology studies
- NYMC 165 – A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2-O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Pediatric Patients With a Recurrent Solid Tumor Receiving “ICE” Chemotherapy (IND 122872)
Non-Hodgkin Lymphoma (Burkitt, Large Cell, Lymphoblastic, Anaplastic)
- NYMC 165 – Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)
- NYMC 542 – A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma
- NYMC 561 – 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
- ANHL12P1 – A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117
- AALL1231 – A Phase III Randomized Trial Investigating Bortezomib on a Modified Augmented BFM Backbone in Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
- ALTE11C1 – Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma
- ANHL04B1 – Rare and Cutaneous Non-Hodgkin’s Lymphoma Registry
- NYMC 166 – ImmunoChemotherapy with Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in children, adolescents and young adults with recurrent refractory CD20+ mature B-NHL
- NYMC 157 – Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma
- NYMC 542 – A Pilot Study of Mitozantrone in Combination with Clofarabone (MITCL) in Children Adolescents and Young Adults (CAYA) with Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma.
- NYMC 561 – A Multicenter Pilot Study of Third Party LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients with Refractory or Relapsed EBV-Associated Lymphoma A Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) Multicenter Clinical Trial
- NYMC 172 – Childhood, Adolescent, and Young Adult (CAYA) Lymphoma/Leukemia Tissue Banking and Biorepository Center (BRC): CAYA L/L BRC
Retinoblastoma
Severe Combined Immunodeficiency
Sickle Cell Disease
- NYMC 526 – Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease – Lead Institution (HaploSCD)
- NYMC 556 – Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients with Sickle Cell Disease and Thalassemia
Solid Tumors
- A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
- D9902 – A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
- NYMC 165 – A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2-O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Pediatric Patients With a Recurrent Solid Tumor Receiving “ICE” Chemotherapy (IND 122872)
- ARST1321 – Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
- A0ST06B1 – Osteosarcoma Biology Studies
- AEWS07B1 – Ewing Sarcoma Biology Studies
- AEWS1031 – A phase III randomized trial of adding vincristine – topotecan- cyclophosphamide to standard chemotherapy in initial treatment of non-metastatic Ewing sarcoma
- AEWS1221 -Randomized phase II trial evaluating the addition of the IGF – 1R monoclonal antibody Ganitumab to multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma
Thalassemia
- NYMC 525 – CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
- 10-CBA – A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- NYMC 556 – Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients with Sickle Cell Disease and Thalassemia
Wellness and Survivorship
- NYMC 168 – Cancer and Blood Marrow Transplantation Wellness and Survivorship Research
Wilms Tumor
- CCG4914L – National Wilms Tumor Late Effects Study
Wiskott-Aldrich
Other
- NYMC – Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
- ACCL1034 – Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)
- ALTE05N1 – Key Adverse Events After Childhood Cancer
- AREN03B2 – Renal Tumors Classification, Biology, and Banking Study
- ALTE05N1 – Umbrella Long-Term Follow-Up Protocol
- ACCRN07 – Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)
- ALTE07C1 – Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
- NYMC 567 – A Multicenter Phase II trial of Inhibitiion of CD26 Peptidase using Sitagliptin To Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults with Hematological Malignancies.
- NYMC 525 – CD34+ Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease
- NYMC154 – Defibrotide for patients with Hepatic Veno-Occlusive Disease (VOD)
- NYMC550 – A Single Arm Study to Assess the Safety of Transplantation with Human Placental-Derived Stem Cells (HPDSC) Combine with Unrelated and Related Cord Blood in Subjects with Certain Malignant Hematologic Diseases and Non-Malignant Disorders
- NYMC 160 – Tumor Banking
- NYMC 163 – Non-Graft Versus Host Disease Skin Changes in Pediatrics Hematopoietic Stem Cell Recipients
- NYMC 164 – Screening and Testing for Lead Toxicity in Hospitalized Children
- NYMC 544 – A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
- NYMC 161 – Prospective multi-center cohort for the Evaluation of Biomarkers predicting risk of complications & mortality following Allogeneic HCT
- NYMC 558 – Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy & Safety of UCB Cells Expanded Ex Vivo with Mesenchymal Precursor Cells for Hematopoietic Recovery in Patients With Hematologic Malignancies After Myeloablative Conditioning
- NYMC 563 – Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic Hematopoietic Cell Transplant (HCT)
- NYMC 557 – NMDP – Protocol For A Research Sample Repository for Allogeneic Hematopoeitic Stem Cell Transplantation and Marrow Toxic Injuries
- NYMC 565 – NMDP/CIBMTR – Protocol For A Research Database for Hematopoeitic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
- NYMC 569 – National Cord Blood Program IND Clinical Trial Agreement